NL1014915C2 - Nieuwe behandelingsmethode. - Google Patents

Nieuwe behandelingsmethode. Download PDF

Info

Publication number
NL1014915C2
NL1014915C2 NL1014915A NL1014915A NL1014915C2 NL 1014915 C2 NL1014915 C2 NL 1014915C2 NL 1014915 A NL1014915 A NL 1014915A NL 1014915 A NL1014915 A NL 1014915A NL 1014915 C2 NL1014915 C2 NL 1014915C2
Authority
NL
Netherlands
Prior art keywords
amoxycillin
release
tablet
potassium clavulanate
slow release
Prior art date
Application number
NL1014915A
Other languages
English (en)
Dutch (nl)
Other versions
NL1014915A1 (nl
Inventor
Kevin Storm
John Roush
Creighton Conley
Original Assignee
Beecham Pharm Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27383840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL1014915(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Pharm Pte Ltd filed Critical Beecham Pharm Pte Ltd
Publication of NL1014915A1 publication Critical patent/NL1014915A1/xx
Application granted granted Critical
Publication of NL1014915C2 publication Critical patent/NL1014915C2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
NL1014915A 1999-04-13 2000-04-11 Nieuwe behandelingsmethode. NL1014915C2 (nl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12907499P 1999-04-13 1999-04-13
US12907499 1999-04-13
US15072799P 1999-08-25 1999-08-25
US15072799 1999-08-25
US15981399P 1999-10-15 1999-10-15
US15981399 1999-10-15

Publications (2)

Publication Number Publication Date
NL1014915A1 NL1014915A1 (nl) 2000-10-16
NL1014915C2 true NL1014915C2 (nl) 2001-02-12

Family

ID=27383840

Family Applications (2)

Application Number Title Priority Date Filing Date
NL1014914A NL1014914C1 (nl) 1999-04-13 2000-04-11 Nieuwe behandelingsmethode.
NL1014915A NL1014915C2 (nl) 1999-04-13 2000-04-11 Nieuwe behandelingsmethode.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NL1014914A NL1014914C1 (nl) 1999-04-13 2000-04-11 Nieuwe behandelingsmethode.

Country Status (45)

Country Link
EP (4) EP1269996A1 (fi)
JP (2) JP4880125B2 (fi)
KR (1) KR100634937B1 (fi)
CN (1) CN100382782C (fi)
AP (1) AP1806A (fi)
AR (1) AR031068A1 (fi)
AT (2) ATE242629T1 (fi)
AU (1) AU767177B2 (fi)
BE (2) BE1012733A6 (fi)
BG (1) BG65006B1 (fi)
BR (1) BRPI0009719B8 (fi)
CA (1) CA2366304C (fi)
CO (1) CO5170471A1 (fi)
CZ (1) CZ298801B6 (fi)
DE (3) DE60003255T2 (fi)
DK (3) DK1044680T3 (fi)
DZ (1) DZ3150A1 (fi)
EA (1) EA004310B1 (fi)
ES (2) ES2190692B1 (fi)
FI (2) FI4823U1 (fi)
FR (1) FR2792198A1 (fi)
GB (1) GB2351661B (fi)
GR (1) GR1003560B (fi)
HK (1) HK1032741A1 (fi)
HU (1) HU229097B1 (fi)
IE (1) IE20000271A1 (fi)
IL (2) IL145580A0 (fi)
IT (1) ITMI20000788A1 (fi)
MA (1) MA25352A1 (fi)
MX (1) MXPA01010377A (fi)
MY (1) MY119953A (fi)
NL (2) NL1014914C1 (fi)
NO (1) NO329694B1 (fi)
NZ (1) NZ514575A (fi)
OA (1) OA11926A (fi)
PE (1) PE20010053A1 (fi)
PL (1) PL197448B1 (fi)
PT (2) PT1044680E (fi)
RO (1) RO120817B1 (fi)
SE (1) SE0001330L (fi)
SI (2) SI20304A (fi)
SK (1) SK285140B6 (fi)
TR (1) TR200102963T2 (fi)
TW (1) TWI235067B (fi)
WO (1) WO2000061116A2 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
BR0205721A (pt) 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
WO2003086267A2 (en) * 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1541129A1 (en) * 2003-12-12 2005-06-15 Cimex AG Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2005099672A1 (en) * 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
EP1880716A1 (en) * 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
EP2079453A1 (en) * 2006-10-10 2009-07-22 Penwest Pharmaceuticals Co. Robust sustained release formulations
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
AU2016246580B2 (en) * 2015-04-07 2020-12-17 Church & Dwight Co., Inc. Multicomponent gummy compositions with hard core
CN109394718B (zh) * 2018-11-15 2021-04-27 石药集团中诺药业（石家庄）有限公司 一种阿莫西林分散片及其制备方法
CN110051637A (zh) * 2019-05-21 2019-07-26 葵花药业集团北京药物研究院有限公司 阿莫西林克拉维酸钾制剂及其制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282202A (en) * 1978-10-27 1981-08-04 Beecham Group Limited Intramammary compositions
WO1991015197A1 (en) * 1990-04-07 1991-10-17 Beecham Group Plc Pharmaceutical formulation
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
WO1995020946A1 (en) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Bilayered amoxycillin tablets
WO1995028148A1 (en) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Pharmaceutical formulation
WO1995033487A1 (en) * 1994-06-06 1995-12-14 Smithkline Beecham Farmaceutici S.P.A. Injectable formulations containing a desiccant
WO1997009042A1 (en) * 1995-09-07 1997-03-13 Smithkline Beecham Corporation Pharmaceutical formulation
WO1998035672A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
WO1998042311A1 (en) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
WO2000012088A1 (en) * 1998-08-28 2000-03-09 Smithkline Beecham Plc Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964817D1 (en) * 1978-09-06 1983-03-24 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
EP0680322B1 (en) * 1993-01-22 2000-07-05 Smithkline Beecham Plc Use of clavulanate and an antibacterial compound for the treatment of infections
GB9311030D0 (en) * 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
WO1998040541A1 (en) * 1997-03-11 1998-09-17 Almag Al Process and apparatus for coating metals
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
JP3746901B2 (ja) * 1997-10-15 2006-02-22 ユニ・チャーム株式会社 開閉自在容器
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
US6225304B1 (en) * 1999-02-17 2001-05-01 Pharmaceutical Solutions, Inc. Soluble forms of amoxicillin and treatment of animals

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282202A (en) * 1978-10-27 1981-08-04 Beecham Group Limited Intramammary compositions
WO1991015197A1 (en) * 1990-04-07 1991-10-17 Beecham Group Plc Pharmaceutical formulation
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations
WO1995020946A1 (en) * 1994-02-04 1995-08-10 Smithkline Beecham Plc Bilayered amoxycillin tablets
WO1995028148A1 (en) * 1994-04-14 1995-10-26 Smithkline Beecham Plc Pharmaceutical formulation
WO1995033487A1 (en) * 1994-06-06 1995-12-14 Smithkline Beecham Farmaceutici S.P.A. Injectable formulations containing a desiccant
WO1997009042A1 (en) * 1995-09-07 1997-03-13 Smithkline Beecham Corporation Pharmaceutical formulation
WO1998035672A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
WO1998042311A1 (en) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Gastrointestinal mucosa-adherent pharmaceutical composition
WO2000012088A1 (en) * 1998-08-28 2000-03-09 Smithkline Beecham Plc Pharmaceutical formulation of sodium amoxycillin and potassium clavulanate

Also Published As

Publication number Publication date
BG65006B1 (bg) 2006-12-29
HUP0001471A2 (en) 2001-03-28
FI4823U1 (fi) 2001-02-16
AP1806A (en) 2007-12-14
SI1044680T1 (en) 2003-12-31
FIU20000164U0 (fi) 2000-04-11
MY119953A (en) 2005-08-30
CZ20001311A3 (cs) 2000-11-15
MA25352A1 (fr) 2001-12-31
PT102450B (pt) 2003-09-30
BR0009719A (pt) 2002-01-08
CA2366304A1 (en) 2000-10-19
BRPI0009719B8 (pt) 2021-05-25
SI20304A (sl) 2001-02-28
FI20000863A0 (fi) 2000-04-11
DZ3150A1 (fr) 2000-10-19
ITMI20000788A1 (it) 2001-10-11
NO20001870L (no) 2000-10-16
KR100634937B1 (ko) 2006-10-17
HUP0001471A3 (en) 2001-10-29
TR200102963T2 (tr) 2002-02-21
CA2366304C (en) 2004-06-29
ATE242629T1 (de) 2003-06-15
JP2011256180A (ja) 2011-12-22
WO2000061116A2 (en) 2000-10-19
AU5702000A (en) 2000-11-14
CN100382782C (zh) 2008-04-23
CO5170471A1 (es) 2002-06-27
NL1014915A1 (nl) 2000-10-16
AR031068A1 (es) 2003-09-10
OA11926A (en) 2006-04-12
DK200000133U3 (da) 2000-07-28
ES2190692B1 (es) 2004-11-16
EA004310B1 (ru) 2004-02-26
EP1270005A3 (en) 2006-05-17
EP1270005A2 (en) 2003-01-02
KR20020015312A (ko) 2002-02-27
HU0001471D0 (en) 2000-06-28
ES2202004T3 (es) 2004-04-01
EA200101075A1 (ru) 2002-04-25
ES2190692A1 (es) 2003-08-01
ITMI20000788A0 (it) 2000-04-11
SK5342000A3 (en) 2000-11-07
AP2001002284A0 (en) 2001-12-31
FI20000863A (fi) 2000-10-13
NO329694B1 (no) 2010-12-06
PT102450A (pt) 2001-02-01
BE1012733A6 (fr) 2001-02-06
EP1269997A1 (en) 2003-01-02
AU767177B2 (en) 2003-11-06
DE60003255D1 (de) 2003-07-17
DE10017883A1 (de) 2000-10-26
EP1269996A1 (en) 2003-01-02
IL145580A0 (en) 2002-11-10
NO20001870D0 (no) 2000-04-11
GB2351661B (en) 2001-10-10
PL197448B1 (pl) 2008-03-31
SK285140B6 (sk) 2006-07-07
EP1044680B1 (en) 2003-06-11
WO2000061116A3 (en) 2001-02-01
SE0001330L (sv) 2000-10-14
HU229097B1 (en) 2013-07-29
SE0001330D0 (sv) 2000-04-11
DE60003255T2 (de) 2004-05-06
FR2792198A1 (fr) 2000-10-20
CN1382040A (zh) 2002-11-27
EP1044680A1 (en) 2000-10-18
PE20010053A1 (es) 2001-03-10
CZ298801B6 (cs) 2008-02-06
RO120817B1 (ro) 2006-08-30
BR0009719B1 (pt) 2014-09-30
GB0008923D0 (en) 2000-05-31
DK1044680T3 (da) 2003-09-29
DK200000602A (da) 2000-10-14
DE20006626U1 (de) 2000-10-19
MXPA01010377A (es) 2002-10-23
HK1032741A1 (en) 2001-08-03
IL145580A (en) 2007-05-15
PL339591A1 (en) 2000-10-23
JP4880125B2 (ja) 2012-02-22
BE1013309A5 (fr) 2001-11-06
IE20000271A1 (en) 2001-04-04
TWI235067B (en) 2005-07-01
GR1003560B (el) 2001-03-16
PT1044680E (pt) 2003-10-31
NZ514575A (en) 2004-05-28
JP2002541187A (ja) 2002-12-03
BG104329A (en) 2001-11-30
NL1014914C1 (nl) 2000-10-16
AT4327U1 (de) 2001-06-25
GB2351661A (en) 2001-01-10

Similar Documents

Publication Publication Date Title
NL1014915C2 (nl) Nieuwe behandelingsmethode.
US6294199B1 (en) Method of treating a bacterial infection comprising administering amoxycillin
US20070104784A1 (en) Compositions and methods of treatment comprising amoxicillin and potassium clavulante with xanthan
US6746692B2 (en) Modified release pharmaceutical formulation comprising amoxycillin
ZA200108321B (en) Novel method of treatment.
GB2365337A (en) Amoxycillin and potassium clavulanate high dosage regimen

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20001206

PD2B A search report has been drawn up
MK Patent expired because of reaching the maximum lifetime of a patent

Effective date: 20200410